查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067668

基於外泌體的治療產品市場規模、佔有率和趨勢分析報告：按產品類型、來源、治療應用、最終用戶、地區和細分市場預測（2026-2033 年）

Exosome-based Therapeutics Market Size, Share & Trends Analysis Report By Product Type, By Source, By Therapeutic Application, By End User, By Region (North America, Europe, Asia Pacific, Middle East & Africa), And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

外泌體療法市場概述

2025 年全球外泌體療法市場價值為 5,628 萬美元，預計到 2033 年將達到 2.202 億美元，而 2026 年為 6,648 萬美元，2026 年至 2033 年的複合年成長率為 18.66%。

到 2025 年，北美外吐小體體療法市場將佔全球市場最大佔有率，達到 39.41%。

基於外泌體的療法市場正作為先進生技藥品和再生醫學領域的下一代細分市場而崛起，其發展動力源於對細胞外囊泡（EVs）作為細胞間通訊和靶向藥物遞送天然載體的研究不斷深入。外泌體因其能夠運輸蛋白質、脂質和核酸，同時具備高生物相容性和低免疫抗原性而備受關注，使其成為精準醫療應用的理想候選者。基因修飾外泌體的研究不斷拓展，尤其是在腫瘤、神經系統疾病和發炎性疾病的治療性藥物傳遞方面，正在推動這一市場的發展。生物技術公司和學術機構日益成長的興趣正在加速轉化研究，而分離、純化和表徵技術的進步則提高了規模化生產和臨床可行性。然而，該領域仍處於發展初期，許多候選產品仍處於臨床前或早期臨床試驗階段。

此外，再生醫學和無細胞療法領域應用範圍的不斷擴大也推動了市場成長。在這些領域，外泌體的研究正朝著組織修復、免疫調節和抗發炎等目標穩步推進。外泌體能夠模擬幹細胞的功能特性，並避免了活細胞移植的風險，這增強了其臨床應用前景。研究的重點領域包括阿茲海默症、帕金森氏症和脊髓損傷等神經系統疾病，研究人員正在評估外泌體克服生物屏障並將治療有效載荷遞送至中樞神經系統的潛力。在腫瘤學領域，外泌體平台正被用於藥物遞送和基於生物標記的診斷，從而實現疾病的早期檢測和個人化治療。儘管科學研究勢頭強勁，但大規模生產、分離技術的標準化以及監管方面的不確定性等挑戰仍然阻礙外泌體的廣泛商業化應用。

投資增加、策略聯盟的建立以及生物技術公司不斷擴大市場准入，正在加速外泌體療法從研究階段向臨床檢驗階段的過渡。各公司正積極致力於外泌體平台的改造、可擴展生產技術的研發以及先進的載藥技術的改進，以提高治療效果和可重複性。目前，市場競爭格局仍高度分散，早期企業眾多，而上市產品數量有限。在北美，由於產學合作的加強和資金投入，研究活動主導；而歐洲和亞太地區參與臨床開發舉措的比例也在增加。總體而言，外泌體療法市場預計將穩步發展，其長期成長潛力將受到生物工程進步、監管政策的完善以及有前景的候選藥物成功臨床應用等因素的推動。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：基於外泌體的治療市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：基於外泌體的治療市場：按產品類型分類的商業分析

  • 按產品類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按產品類型分類，2021-2033 年
  • 天然外泌體療法
  • 預先設計的外泌體療法
  • 基於外泌體的藥物遞送療法
  • 混合外泌體療法

第5章：基於外泌體的治療市場：依來源分類的商業分析

  • 按來源分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按來源分類，2021-2033 年
  • 間質幹細胞（MSC）來源的外泌體
  • 免疫細胞來源的外泌體
  • 癌細胞來源的外泌體
  • 源自血漿和生物體液的外泌體
  • 其他細胞來源的外泌體

第6章：以外泌體為基礎的治療市場：依治療應用進行商業分析

  • 按治療應用分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按治療應用分類，2021-2033年
  • 腫瘤學
  • 神經病學
  • 心血管疾病
  • 免疫學和發炎性疾病
  • 皮膚科和再生醫學
  • 感染疾病
  • 罕見疾病
  • 其他治療用途

第7章：以外泌體為基礎的治療市場：依最終使用者分類的商業分析

  • 按最終用戶分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按最終用戶分類，2021-2033 年
  • 製藥和生物技術公司
  • 研究和學術機構
  • 合約研發生產組織（CDMO/CRO）
  • 醫院和專科診所

第8章：基於外泌體的治療市場：區域估算和趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Codiak BioSciences
    • Evox Therapeutics
    • Capricor Therapeutics
    • Aegle Therapeutics
    • Exopharm
    • ExoCoBio
    • Kimera Labs
    • Aruna Bio
    • Direct Biologics
    • ReNeuron Group plc
Product Code: GVR-4-68040-925-0

Exosome-based Therapeutics Market Summary

The global exosome-based therapeutics market size was valued at USD 56.28 million in 2025, is anticipated to grow from USD 66.48 million in 2026 to reach USD 220.20 million by 2033, growing at a CAGR of 18.66% from 2026 to 2033. North America exosome-based therapeutics market held the largest share of 39.41% of the global market in 2025.

The exosome-based therapeutics market is emerging as a next-generation segment within advanced biologics and regenerative medicine, driven by the increasing exploration of extracellular vesicles (EVs) as natural carriers for intercellular communication and targeted drug delivery. Exosomes are gaining attention due to their ability to transport proteins, lipids, and nucleic acids with high biocompatibility and low immunogenicity, making them attractive candidates for precision medicine applications. The market is being shaped by growing research into engineered exosomes for therapeutic delivery, particularly in oncology, neurology, and inflammatory disorders. Increasing interest from biotechnology companies and academic institutions is accelerating translational research, while advancements in isolation, purification, and characterization technologies are improving scalability and clinical feasibility. However, the field is still in an early developmental stage, with most candidates in preclinical or early clinical phases.

The market is further supported by expanding applications in regenerative medicine and cell-free therapies, where exosomes are being investigated for tissue repair, immune modulation, and anti-inflammatory effects. Their ability to mimic the functional properties of stem cells without the risks associated with live-cell transplantation is strengthening their clinical appeal. Key research areas include neurological disorders such as Alzheimer's disease, Parkinson's disease, and spinal cord injuries, where exosomes are being evaluated for their potential to cross biological barriers and deliver therapeutic payloads to the central nervous system. In oncology, exosome platforms are being explored for both drug delivery and biomarker-based diagnostics, enabling earlier disease detection and personalized treatment approaches. Despite strong scientific momentum, challenges such as large-scale manufacturing, standardization of isolation techniques, and regulatory uncertainty continue to limit widespread commercialization.

Increasing investments, strategic collaborations, and rising participation from biotechnology companies are accelerating the transition of exosome-based therapeutics from research to clinical validation. Companies are actively focusing on engineered exosome platforms, scalable production technologies, and advanced cargo-loading methods to enhance therapeutic efficiency and reproducibility. The competitive landscape remains highly fragmented, with multiple early-stage players and limited commercial products currently available. North America dominates research activity due to strong academic-industry collaboration and funding support, while Europe and Asia Pacific are witnessing increasing participation in clinical development initiatives. Overall, the exosome-based therapeutics market is expected to evolve gradually, with long-term growth potential driven by advancements in bioengineering, regulatory clarity, and successful clinical translation of lead candidates.

Global Exosome-based Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global exosome-based therapeutics market report based on product type, source, therapeutic application, end user, and region:

  • Product Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Native Exosome Therapeutics
  • Engineered Exosome Therapeutics
  • Exosome-based Drug Delivery Therapeutics
  • Hybrid Exosome Therapeutics
  • Source Outlook (Revenue, USD Million, 2021 - 2033)
  • Mesenchymal Stem Cell (MSC)-Derived Exosomes
  • Immune Cell-Derived Exosomes
  • Tumor Cell-Derived Exosomes
  • Plasma/Biofluid-Derived Exosomes
  • Other Cell Source-Derived Exosomes
  • Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology
  • Cardiovascular Diseases
  • Immunology & Inflammatory Diseases
  • Dermatology & Regenerative Medicine
  • Infectious Diseases
  • Rare Diseases
  • Other Therapeutic Applications
  • End User Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Contract Development & Manufacturing Organizations (CDMOs/CROs)
  • Hospitals & Specialty Clinics
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Source
    • 1.2.3. Therapeutic Application
    • 1.2.4. End User
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Exosome-based Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Exosome-based Therapeutics Market: Product Type Business Analysis

  • 4.1. Product Type Market Share, 2025 & 2033
  • 4.2. Product Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
  • 4.4. Native Exosome Therapeutics
    • 4.4.1. Native Exosome Therapeutics Market, 2021 - 2033 (USD Million)
  • 4.5. Engineered Exosome Therapeutics
    • 4.5.1. Engineered Exosome Therapeutics Market, 2021 - 2033 (USD Million)
  • 4.6. Exosome-based Drug Delivery Therapeutics
    • 4.6.1. Exosome-based Drug Delivery Therapeutics Market, 2021 - 2033 (USD Million)
  • 4.7. Hybrid Exosome Therapeutics
    • 4.7.1. Hybrid Exosome Therapeutics Market, 2021 - 2033 (USD Million)

Chapter 5. Exosome-based Therapeutics Market: Source Business Analysis

  • 5.1. Source Market Share, 2025 & 2033
  • 5.2. Source Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Source, 2021 to 2033 (USD Million)
  • 5.4. Mesenchymal Stem Cell (MSC)-Derived Exosomes
    • 5.4.1. Mesenchymal Stem Cell (MSC)-Derived Exosomes Market, 2021 - 2033 (USD Million)
  • 5.5. Immune Cell-Derived Exosomes
    • 5.5.1. Immune Cell-Derived Exosomes Market, 2021 - 2033 (USD Million)
  • 5.6. Tumor Cell-Derived Exosomes
    • 5.6.1. Tumor Cell-Derived Exosomes Market, 2021 - 2033 (USD Million)
  • 5.7. Plasma/Biofluid-Derived Exosomes
    • 5.7.1. Plasma/Biofluid-Derived Exosomes Market, 2021 - 2033 (USD Million)
  • 5.8. Other Cell Source-Derived Exosomes
    • 5.8.1. Other Cell Source-Derived Exosomes Market, 2021 - 2033 (USD Million)

Chapter 6. Exosome-based Therapeutics Market: Therapeutic Application Business Analysis

  • 6.1. Therapeutic Application Market Share, 2025 & 2033
  • 6.2. Therapeutic Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Application, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market, 2021 - 2033 (USD Million)
  • 6.5. Neurology
    • 6.5.1. Neurology Market, 2021 - 2033 (USD Million)
  • 6.6. Cardiovascular Diseases
    • 6.6.1. Cardiovascular Diseases Market, 2021 - 2033 (USD Million)
  • 6.7. Immunology & Inflammatory Diseases
    • 6.7.1. Immunology & Inflammatory Diseases Market, 2021 - 2033 (USD Million)
  • 6.8. Dermatology & Regenerative Medicine
    • 6.8.1. Dermatology & Regenerative Medicine Market, 2021 - 2033 (USD Million)
  • 6.9. Infectious Diseases
    • 6.9.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 6.10. Rare Diseases
    • 6.10.1. Rare Diseases Market, 2021 - 2033 (USD Million)
  • 6.11. Other Therapeutic Applications
    • 6.11.1. Other Therapeutic Applications Market, 2021 - 2033 (USD Million)

Chapter 7. Exosome-based Therapeutics Market: End User Business Analysis

  • 7.1. End User Market Share, 2025 & 2033
  • 7.2. End User Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
  • 7.5. Research & Academic Institutes
    • 7.5.1. Research & Academic Institutes Market, 2021 - 2033 (USD Million)
  • 7.6. Contract Development & Manufacturing Organizations (CDMOs/CROs)
    • 7.6.1. Contract Development & Manufacturing Organizations (CDMOs/CROs) Market, 2021 - 2033 (USD Million)
  • 7.7. Hospitals & Specialty Clinics
    • 7.7.1. Hospitals & Specialty Clinics Market, 2021 - 2033 (USD Million)

Chapter 8. Exosome-based Therapeutics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Exosome-based Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Codiak BioSciences
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Evox Therapeutics
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Capricor Therapeutics
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Aegle Therapeutics
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Exopharm
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. ExoCoBio
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Kimera Labs
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Aruna Bio
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Direct Biologics
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. ReNeuron Group plc
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global exosome-based therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 5 Global exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 6 Global exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 7 Global exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 8 North America exosome-based therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 10 North America exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 11 North America exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 12 North America exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 13 U.S. exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 14 U.S. exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 15 U.S. exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 16 U.S. exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 17 Canada exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 18 Canada exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 19 Canada exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 20 Canada exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 21 Mexico exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 22 Mexico exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 23 Mexico exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 24 Mexico exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 25 Europe exosome-based therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 27 Europe exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 28 Europe exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 29 Europe exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 30 UK exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 31 UK exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 32 U.K. exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 33 UK exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 34 Germany exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 35 Germany exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 36 Germany exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 37 Germany exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 38 France exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 39 France exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 40 France exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 41 France exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 42 Italy exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 43 Italy exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 44 Italy exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 45 Italy exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 46 Spain exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 47 Spain exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 48 Spain exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 49 Spain exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 50 Norway exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 51 Norway exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 52 Norway exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 53 Norway exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 54 Denmark exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 55 Denmark exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 56 Denmark exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 57 Denmark exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 58 Sweden exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 59 Sweden exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 60 Sweden exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 61 Sweden exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific exosome-based therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 67 Japan exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 68 Japan exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 69 Japan exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 70 Japan exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 71 China exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 72 China exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 73 China exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 74 China exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 75 India exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 76 India exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 77 India exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 78 India exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 79 Australia exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 80 Australia exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 81 Australia exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 82 Australia exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 83 South Korea exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 84 South Korea exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 85 South Korea exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 86 South Korea exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 87 Thailand exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 88 Thailand exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 89 Thailand exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 90 Thailand exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 91 Latin America exosome-based therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 93 Latin America exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 94 Latin America exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 95 Latin America exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 96 Brazil exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 97 Brazil exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 98 Brazil exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 99 Brazil exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 100 Argentina exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 101 Argentina exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 102 Argentina exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 103 Argentina exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa exosome-based therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 109 South Africa exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 110 South Africa exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 111 South Africa exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 112 South Africa exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 117 UAE exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 118 UAE exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 119 UAE exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 120 UAE exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)
  • Table 121 Kuwait exosome-based therapeutics market, by product type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait exosome-based therapeutics market, by source, 2021 - 2033 (USD Million)
  • Table 123 Kuwait exosome-based therapeutics market, by therapeutic application, 2021 - 2033 (USD Million)
  • Table 124 Kuwait exosome-based therapeutics market, by end user, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Exosome-based therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Exosome-based therapeutics market dynamics
  • Fig. 11 Exosome-based therapeutics market: Porter's five forces analysis
  • Fig. 12 Exosome-based therapeutics market: PESTLE analysis
  • Fig. 13 Product type market, 2021 - 2033 (USD Million)
  • Fig. 14 Native exosome therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 15 Engineered exosome therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 16 Exosome-based drug delivery therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 17 Hybrid exosome therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 18 Source market, 2021 - 2033 (USD Million)
  • Fig. 19 Mesenchymal stem cell (MSC)-derived exosomes market, 2021 - 2033 (USD Million)
  • Fig. 20 Immune cell-derived exosomes market, 2021 - 2033 (USD Million)
  • Fig. 21 Tumor cell-derived exosomes market, 2021 - 2033 (USD Million)
  • Fig. 22 Plasma/biofluid-derived exosomes market, 2021 - 2033 (USD Million)
  • Fig. 23 Other cell source-derived exosomes market, 2021 - 2033 (USD Million)
  • Fig. 24 Therapeutic application market, 2021 - 2033 (USD Million)
  • Fig. 25 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 26 Neurology market, 2021 - 2033 (USD Million)
  • Fig. 27 Cardiovascular diseases market, 2021 - 2033 (USD Million)
  • Fig. 28 Immunology & inflammatory diseases market, 2021 - 2033 (USD Million)
  • Fig. 29 Dermatology & regenerative medicine market, 2021 - 2033 (USD Million)
  • Fig. 30 Infectious diseases market, 2021 - 2033 (USD Million)
  • Fig. 31 Rare diseases market, 2021 - 2033 (USD Million)
  • Fig. 32 Other therapeutic applications market, 2021 - 2033 (USD Million)
  • Fig. 33 End user market, 2021 - 2033 (USD Million)
  • Fig. 34 Pharmaceutical & biotechnology companies market, 2021 - 2033 (USD Million)
  • Fig. 35 Research & academic institutes market, 2021 - 2033 (USD Million)
  • Fig. 36 Contract development & manufacturing organizations (CDMOs/CROs) market, 2021 - 2033 (USD Million)
  • Fig. 37 Hospitals & specialty clinics market, 2021 - 2033 (USD Million)
  • Fig. 38 Exosome-based therapeutics market revenue, by region
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. country dynamics
  • Fig. 42 U.S. Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Canada country dynamics
  • Fig. 44 Canada Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Mexico country dynamics
  • Fig. 46 Mexico Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Europe Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 UK country dynamics
  • Fig. 49 UK Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Germany country dynamics
  • Fig. 51 Germany Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 France country dynamics
  • Fig. 53 France Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Italy country dynamics
  • Fig. 55 Italy Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Spain country dynamics
  • Fig. 57 Spain Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Norway country dynamics
  • Fig. 59 Norway Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Sweden country dynamics
  • Fig. 61 Sweden Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Denmark country dynamics
  • Fig. 63 Denmark Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 Asia Pacific Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Japan country dynamics
  • Fig. 66 Japan Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 China country dynamics
  • Fig. 68 China Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 India country dynamics
  • Fig. 70 India Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Australia country dynamics
  • Fig. 72 Australia Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 South Korea country dynamics
  • Fig. 74 South Korea Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 75 Thailand country dynamics
  • Fig. 76 Thailand Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 77 Latin America Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Brazil country dynamics
  • Fig. 79 Brazil Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 80 Argentina country dynamics
  • Fig. 81 Argentina Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 82 MEA Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 South Africa country dynamics
  • Fig. 84 South Africa Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 85 Saudi Arabia country dynamics
  • Fig. 86 Saudi Arabia Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 87 UAE country dynamics
  • Fig. 88 UAE Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 89 Kuwait country dynamics
  • Fig. 90 Kuwait Exosome-based therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 91 Company categorization
  • Fig. 92 Company market position analysis
  • Fig. 93 Strategic framework